Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Depreciation and Depletion (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Depreciation and Depletion for 7 consecutive years, with $400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 20.48% year-over-year to $400000.0, compared with a TTM value of $1.5 million through Dec 2025, up 22.78%, and an annual FY2025 reading of $1.5 million, up 22.78% over the prior year.
  • Depreciation and Depletion was $400000.0 for Q4 2025 at Keros Therapeutics, up from $395000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $400000.0 in Q4 2025 and bottomed at $80000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $230250.0, with a median of $228500.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion soared 238.46% in 2022, then tumbled 37.99% in 2023.
  • Year by year, Depreciation and Depletion stood at $104000.0 in 2021, then grew by 22.12% to $127000.0 in 2022, then surged by 94.49% to $247000.0 in 2023, then skyrocketed by 34.41% to $332000.0 in 2024, then rose by 20.48% to $400000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for KROS at $400000.0 in Q4 2025, $395000.0 in Q3 2025, and $370000.0 in Q2 2025.